Skip to main content
Erschienen in: Journal of Genetic Counseling 1/2015

01.02.2015 | Original Research

A Pilot Study of BRCA Mutation Carriers’ Knowledge About the Clinical Impact of Prophylactic-oophorectomy and Views on Fertility Consultation: A Single-Center Pilot Study

verfasst von: J. Kim, C. Skrzynia, J. E. Mersereau

Erschienen in: Journal of Genetic Counseling | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

BRCA mutation carriers will experience early surgically induced menopause following prophylactic bilateral salpingo-oophorectomy (PBSO). This pilot study aimed to investigate their (1) knowledge about the clinical impact of PBSO; (2) views on fertility consultation (FC)/fertility preservation (FP) treatment; and (3) difficulties in conceiving compared to non-carriers. A cross-sectional, single institution web-survey was performed at a university-based IVF center. Women aged 18–50 years who were screened for BRCA gene mutations from 2005 to 2013 were recruited via mail. Forty-one BRCA-positive and 110 BRCA-negative women completed the survey (response rate: 50 %). The knowledge about the reproductive impact of PBSO was limited, with the majority of women in this highly educated sample only identifying the correct response 64 % of the time. Among BRCA mutation carriers, 24 (59 %) had positive views about FC/FP treatments. A larger proportion of women with no children at the time of BRCA testing, and those who were non-white tended to have positive views toward FP. Women with, versus without, BRCA mutations were more likely to have difficulty in conceiving (p = 0.08). This well-educated group had limited knowledge about the reproductive clinical impact of PBSO, or the benefit of a FP before PBSO. Most women with BRCA mutations were interested in FC/FP treatment if they had not completed childbearing at the time of screening. Targeted referrals for FC at the time of BRCA screening may help women improve knowledge and allow improved decision-making about reproductive options.
Literatur
Zurück zum Zitat ACOG Practice Bulletin No. 103. (2009). Hereditary breast and ovarian cancer syndrome. Obstetrics and Gynecology, 113, 957–966.CrossRef ACOG Practice Bulletin No. 103. (2009). Hereditary breast and ovarian cancer syndrome. Obstetrics and Gynecology, 113, 957–966.CrossRef
Zurück zum Zitat Balthazar, U., Fritz, M. A., & Mersereau, J. E. (2011). Fertility preservation: a pilot study to assess previsit patient knowledge quantitatively. Fertility and Sterility, 95(6), 1913–1916.CrossRef Balthazar, U., Fritz, M. A., & Mersereau, J. E. (2011). Fertility preservation: a pilot study to assess previsit patient knowledge quantitatively. Fertility and Sterility, 95(6), 1913–1916.CrossRef
Zurück zum Zitat Bray, F., McCarron, P., & Parkin, D. M. (2004). The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Research, 6(6), 229–239.CrossRef Bray, F., McCarron, P., & Parkin, D. M. (2004). The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Research, 6(6), 229–239.CrossRef
Zurück zum Zitat Campfield Bonadies, D., Moyer, A., & Matloff, E. T. (2011). What I wish I’d known before surgery: BRCA carriers’ perspectives after bilateral salipingo-oophorectomy. Familial Cancer, 10(1), 79–85.CrossRef Campfield Bonadies, D., Moyer, A., & Matloff, E. T. (2011). What I wish I’d known before surgery: BRCA carriers’ perspectives after bilateral salipingo-oophorectomy. Familial Cancer, 10(1), 79–85.CrossRef
Zurück zum Zitat Couch, F. J., Wang, X., McGuffog, L., Lee, A., Olswold, C., Kuchenbaecker, K. B., et al. (2013). Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genetics, 9(3), e1003212.CrossRef Couch, F. J., Wang, X., McGuffog, L., Lee, A., Olswold, C., Kuchenbaecker, K. B., et al. (2013). Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genetics, 9(3), e1003212.CrossRef
Zurück zum Zitat Eisen, A., Lubinski, J., Klijn, J., Moller, P., Lynch, H. T., Offit, K., et al. (2005). Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case–control study. Journal of Clinical Oncology, 23(30), 7491–7496.CrossRef Eisen, A., Lubinski, J., Klijn, J., Moller, P., Lynch, H. T., Offit, K., et al. (2005). Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case–control study. Journal of Clinical Oncology, 23(30), 7491–7496.CrossRef
Zurück zum Zitat Finch, A., Valentini, A., Greenblatt, E., Lynch, H. T., Ghadirian, P., Armel, S., et al. (2013). Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. Fertility and Sterility, 99(6), 1724–1728.CrossRef Finch, A., Valentini, A., Greenblatt, E., Lynch, H. T., Ghadirian, P., Armel, S., et al. (2013). Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. Fertility and Sterility, 99(6), 1724–1728.CrossRef
Zurück zum Zitat Garcia-Cruz, R., Roig, I., Robles, P., Scjertjam, H., & Garcia-Caldes, M. (2009). ATR, BRCA1 and gammaH2AX localize to unsynapsed chromosomes at the pachytene stage in human oocytes. Reproductive Biomedicine Online, 18(1), 37–44.CrossRef Garcia-Cruz, R., Roig, I., Robles, P., Scjertjam, H., & Garcia-Caldes, M. (2009). ATR, BRCA1 and gammaH2AX localize to unsynapsed chromosomes at the pachytene stage in human oocytes. Reproductive Biomedicine Online, 18(1), 37–44.CrossRef
Zurück zum Zitat Gaudet, M. M., Kuchenbaecker, K. B., Vijai, J., Klein, R. J., Kirchhoff, T., McGuffog, L., et al. (2013). Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genetics, 9(3), e1003173.CrossRef Gaudet, M. M., Kuchenbaecker, K. B., Vijai, J., Klein, R. J., Kirchhoff, T., McGuffog, L., et al. (2013). Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genetics, 9(3), e1003173.CrossRef
Zurück zum Zitat Gnoth, C., Godehardt, E., Frank-Herrmann, P., Friol, K., Tigges, J., & Freundl, G. (2005). Definition and prevalence of subfertility and infertility. Human Reproduction, 20(5), 1144–1147.CrossRef Gnoth, C., Godehardt, E., Frank-Herrmann, P., Friol, K., Tigges, J., & Freundl, G. (2005). Definition and prevalence of subfertility and infertility. Human Reproduction, 20(5), 1144–1147.CrossRef
Zurück zum Zitat Goodman, L. R., Balthazar, U., Kim, J., & Mersereau, J. E. (2012). Trends of socioeconomic disparities in referral patterns for fertility preservation consultation. Human Reproduction, 27(7), 2076–2081.CrossRef Goodman, L. R., Balthazar, U., Kim, J., & Mersereau, J. E. (2012). Trends of socioeconomic disparities in referral patterns for fertility preservation consultation. Human Reproduction, 27(7), 2076–2081.CrossRef
Zurück zum Zitat Hallowell, N. (2000). A qualitative study of the information needs of high-risk women undergoing prophylactic oophorectomy. Psychooncology, 9(6), 486–495.CrossRef Hallowell, N. (2000). A qualitative study of the information needs of high-risk women undergoing prophylactic oophorectomy. Psychooncology, 9(6), 486–495.CrossRef
Zurück zum Zitat Howard, A. F., Balneaves, L. G., Bottorff, J. L., & Rodney, P. (2009). Preserving the self: the process of decision making about hereditary breast cancer and ovarian cancer risk reduction. Qula Health Research, 21(4), 502–519.CrossRef Howard, A. F., Balneaves, L. G., Bottorff, J. L., & Rodney, P. (2009). Preserving the self: the process of decision making about hereditary breast cancer and ovarian cancer risk reduction. Qula Health Research, 21(4), 502–519.CrossRef
Zurück zum Zitat Howard, A. F., Bottorff, J. L., Balneaves, L. G., & Kim-Sing, C. (2010). Women’s constructions of the ‘right time’ to consider decisions about risk-reducing mastectomy and risk-reducing oophorectomy. BMC Womens Health, 10(24), 1–12. Howard, A. F., Bottorff, J. L., Balneaves, L. G., & Kim-Sing, C. (2010). Women’s constructions of the ‘right time’ to consider decisions about risk-reducing mastectomy and risk-reducing oophorectomy. BMC Womens Health, 10(24), 1–12.
Zurück zum Zitat Kaplowitz, H. T., & Levine, R. (2004). A comparison of web and mail survey response rates. Public Opinion Quartely, 68, 94–101.CrossRef Kaplowitz, H. T., & Levine, R. (2004). A comparison of web and mail survey response rates. Public Opinion Quartely, 68, 94–101.CrossRef
Zurück zum Zitat Kauff, N. D., Satagopan, J. M., Robson, M. E., Scheuer, L., Hensley, M., Hudis, C. A., et al. (2002). Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. New England Journal of Medicine, 346(21), 1609–1615.CrossRef Kauff, N. D., Satagopan, J. M., Robson, M. E., Scheuer, L., Hensley, M., Hudis, C. A., et al. (2002). Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. New England Journal of Medicine, 346(21), 1609–1615.CrossRef
Zurück zum Zitat Key, T., Appleby, P., Barnes, I., & Reeves, G. (2002). Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. Journal of the National Cancer Institute, 94(8), 606–616.CrossRef Key, T., Appleby, P., Barnes, I., & Reeves, G. (2002). Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. Journal of the National Cancer Institute, 94(8), 606–616.CrossRef
Zurück zum Zitat Kim, J., & Oktay, K. (2013). Baseline E (2) levels are higher in BRCA2 mutation carriers: a potential target for prevention? Cancer Causes and Control, 24(3), 421–426.CrossRef Kim, J., & Oktay, K. (2013). Baseline E (2) levels are higher in BRCA2 mutation carriers: a potential target for prevention? Cancer Causes and Control, 24(3), 421–426.CrossRef
Zurück zum Zitat Kim, J., Oktay, K., Gracia, C., Lee, S., Morse, C., & Mersereau, J. E. (2012). Which patients pursue fertility preservation treatments? A multicenter analysis of the predictors of fertility preservation in women with breast cancer. Fertility and Sterility, 97(3), 671–676.CrossRef Kim, J., Oktay, K., Gracia, C., Lee, S., Morse, C., & Mersereau, J. E. (2012). Which patients pursue fertility preservation treatments? A multicenter analysis of the predictors of fertility preservation in women with breast cancer. Fertility and Sterility, 97(3), 671–676.CrossRef
Zurück zum Zitat Lin, W. T., Beattie, M., Chen, L. M., Oktay, K., Crawford, S. L., Gold, E. B., et al. (2013). Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California. Cancer, 119(9), 1652–9.CrossRef Lin, W. T., Beattie, M., Chen, L. M., Oktay, K., Crawford, S. L., Gold, E. B., et al. (2013). Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California. Cancer, 119(9), 1652–9.CrossRef
Zurück zum Zitat Loren, A. W., Mangu, P. B., Beck, L. N., Brennan, L., Maqdalinski, A. J., Partridge, A. H., et al. (2013). Fertility preservation for patients with cancer: American society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology, 31(19), 2500–2510.CrossRef Loren, A. W., Mangu, P. B., Beck, L. N., Brennan, L., Maqdalinski, A. J., Partridge, A. H., et al. (2013). Fertility preservation for patients with cancer: American society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology, 31(19), 2500–2510.CrossRef
Zurück zum Zitat Meijers-Heijboer, E. J., Verhoog, L. C., Brekelmans, C. T., Seynaeve, C., Tilanus-Linthorst, M. M., Wagner, A., et al. (2000). Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet, 355(9220), 2015–2020.CrossRef Meijers-Heijboer, E. J., Verhoog, L. C., Brekelmans, C. T., Seynaeve, C., Tilanus-Linthorst, M. M., Wagner, A., et al. (2000). Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet, 355(9220), 2015–2020.CrossRef
Zurück zum Zitat Moslehi, R., Singh, R., Lessner, L., & Friedman, J. M. (2010). Impact of BRCA mutations on female fertility and offspring sex ratio. American Journal of Human Biology, 22(2), 201–205.PubMedPubMedCentral Moslehi, R., Singh, R., Lessner, L., & Friedman, J. M. (2010). Impact of BRCA mutations on female fertility and offspring sex ratio. American Journal of Human Biology, 22(2), 201–205.PubMedPubMedCentral
Zurück zum Zitat Oktay, K., Kim, J. Y., Barad, D., & Babayev, S. N. (2010). Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. Journal of Clinical Oncology, 28(2), 240–244.CrossRef Oktay, K., Kim, J. Y., Barad, D., & Babayev, S. N. (2010). Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. Journal of Clinical Oncology, 28(2), 240–244.CrossRef
Zurück zum Zitat Pal, T., Keefe, D., Sun, P., & Narod, S. A. (2010). Fertility in women with BRCA mutations: a case–control study. Fertility and Sterility, 93(6), 1805–1808.CrossRef Pal, T., Keefe, D., Sun, P., & Narod, S. A. (2010). Fertility in women with BRCA mutations: a case–control study. Fertility and Sterility, 93(6), 1805–1808.CrossRef
Zurück zum Zitat Peate, M., Meiser, B., Friedlander, M., Zorbas, H., Rovelli, S., Samsom-Daly, U., et al. (2011). It’s now or never: fertility-related, decision-making preferences, and treatment intentions in young women with breast cancer—an Australian fertility decision aid collaborative group study. Journal of Clinical Oncology, 29(13), 1670–1677.CrossRef Peate, M., Meiser, B., Friedlander, M., Zorbas, H., Rovelli, S., Samsom-Daly, U., et al. (2011). It’s now or never: fertility-related, decision-making preferences, and treatment intentions in young women with breast cancer—an Australian fertility decision aid collaborative group study. Journal of Clinical Oncology, 29(13), 1670–1677.CrossRef
Zurück zum Zitat Quinn, G. P., Vadaparampil, S. T., Tollin, S., Miree, C. A., Murphy, D., Bower, B., et al. (2010). BRCA carriers’ thoughts on risk management in relation to preimplantation genetic diagnosis and childbearing: when too many choices are just as difficult as none. Fertility and Sterility, 94(6), 2473–2475.CrossRef Quinn, G. P., Vadaparampil, S. T., Tollin, S., Miree, C. A., Murphy, D., Bower, B., et al. (2010). BRCA carriers’ thoughts on risk management in relation to preimplantation genetic diagnosis and childbearing: when too many choices are just as difficult as none. Fertility and Sterility, 94(6), 2473–2475.CrossRef
Zurück zum Zitat Rebbeck, T. R., Levin, A. M., Eisen, A., Snyder, C., Watson, P., Cannon-Albright, L., et al. (1999). Breast cancer risk after bilateral ctic oophorectomy in BRCA1 mutation carriers. Journal of the National Cancer Institute, 91(17), 1475–1479.CrossRef Rebbeck, T. R., Levin, A. M., Eisen, A., Snyder, C., Watson, P., Cannon-Albright, L., et al. (1999). Breast cancer risk after bilateral ctic oophorectomy in BRCA1 mutation carriers. Journal of the National Cancer Institute, 91(17), 1475–1479.CrossRef
Zurück zum Zitat Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., Van’t Veer, L., Garber, J. E., et al. (2002). Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. New England Journal of Medicine, 346(21), 1616–1622.CrossRef Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., Van’t Veer, L., Garber, J. E., et al. (2002). Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. New England Journal of Medicine, 346(21), 1616–1622.CrossRef
Zurück zum Zitat Sharan, S. K., Pyle, A., Coppola, V., Babus, J., Swaminathan, S., Benedict, J., et al. (2004). BRCA2 deficiency in mice leads to meiotic impairment and infertility. Development, 131(1), 131–142.CrossRef Sharan, S. K., Pyle, A., Coppola, V., Babus, J., Swaminathan, S., Benedict, J., et al. (2004). BRCA2 deficiency in mice leads to meiotic impairment and infertility. Development, 131(1), 131–142.CrossRef
Zurück zum Zitat Swisher, E. M., Babb, S., Whelan, A., Mutch, D. G., & Rader, J. S. (2001). Prophylactic oophorectomy and ovarian cancer surveillance. Patient perceptions and satisfaction. Journal of Reproductive Medicine, 46(2), 87–94.PubMed Swisher, E. M., Babb, S., Whelan, A., Mutch, D. G., & Rader, J. S. (2001). Prophylactic oophorectomy and ovarian cancer surveillance. Patient perceptions and satisfaction. Journal of Reproductive Medicine, 46(2), 87–94.PubMed
Zurück zum Zitat The American Association for Public Opinion Research. (2000). Standard definitions: final dispositions of case codes and outcome rates for surveys. Lenexa: The American Association for Public Opinion Research. The American Association for Public Opinion Research. (2000). Standard definitions: final dispositions of case codes and outcome rates for surveys. Lenexa: The American Association for Public Opinion Research.
Zurück zum Zitat Titus, S., Li, F., Stobezki, R., Akula, K., Unsal, E., Jeong, K., et al. (2013). Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Science Translational Medicine, 5(172), 172ra21.CrossRef Titus, S., Li, F., Stobezki, R., Akula, K., Unsal, E., Jeong, K., et al. (2013). Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Science Translational Medicine, 5(172), 172ra21.CrossRef
Metadaten
Titel
A Pilot Study of BRCA Mutation Carriers’ Knowledge About the Clinical Impact of Prophylactic-oophorectomy and Views on Fertility Consultation: A Single-Center Pilot Study
verfasst von
J. Kim
C. Skrzynia
J. E. Mersereau
Publikationsdatum
01.02.2015
Verlag
Springer US
Erschienen in
Journal of Genetic Counseling / Ausgabe 1/2015
Print ISSN: 1059-7700
Elektronische ISSN: 1573-3599
DOI
https://doi.org/10.1007/s10897-014-9747-y

Weitere Artikel der Ausgabe 1/2015

Journal of Genetic Counseling 1/2015 Zur Ausgabe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

22.04.2024 DGIM 2024 Kongressbericht

Durch die Häufung nach der COVID-19-Pandemie sind Infektionen mit dem Respiratorischen Synzytial-Virus (RSV) in den Fokus gerückt. Fachgesellschaften empfehlen eine Impfung inzwischen nicht nur für Säuglinge und Kleinkinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.